A5072326299- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Congenital Heart Disease Studies
- Vascular Anomalies and Treatments
- Cardiac Arrhythmias and Treatments
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Liver Disease and Transplantation
- Blood Pressure and Hypertension Studies
- Hormonal Regulation and Hypertension
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Renin-Angiotensin System Studies
- Long-Term Effects of COVID-19
- Cardiac Imaging and Diagnostics
- Renal and Vascular Pathologies
- COVID-19 Clinical Research Studies
- Cardiac Arrest and Resuscitation
- Hormonal and reproductive studies
- Economic Sanctions and International Relations
- Cardiac Health and Mental Health
- Tracheal and airway disorders
- Cardiovascular Effects of Exercise
- Cardiovascular Disease and Adiposity
- Venous Thromboembolism Diagnosis and Management
- Connective Tissue Growth Factor Research
National Medical Research Center of Cardiology
2016-2025
Research Medical Center
2023
Pirogov Russian National Research Medical University
2021
Institute of Experimental Cardiology
2014-2019
Ministry of Health of the Russian Federation
2017
.
The Russian Society of Cardiology (RSC) With the participation of: Association Cardiovascular Surgeons, Eurasian (EAC), Medical on Arterial Hypertension (RMSAH), Respiratory (RRS), Anesthesiologists and Intensive Care Specialists, Radiologists (RSRR), Rheumatologists Russia. Endorsed by Research Practical Council Ministry Health Federation (12.09.2024).
Disclaimer The EAC Guidelines represent the views of EAC, and were produced after careful consideration scientific medical knowledge, evidence available at time their publication. is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies. Health professionals are encouraged take fully into account when...
On December 13, 2024, the final working group meeting was held, purpose of which to discuss common position experts on problem chronic thromboembolic pulmonary hypertension various specialties: cardiologists, cardiac surgeons, pulmonologists, issues assessing operability patients, risk stratification and choice therapy in patients with inoperable residual forms pathology. The discussion field included a wide range that often arise real clinical practice, but specific answers them are not...
To study demographic and clinical characteristics to give a comparative description of the functional hemodynamic status, profile concomitant pathology in patients with various forms pulmonary arterial hypertension (PAH), chronic thromboembolic (CTEPH) according Russian National Registry.During period from January 01, 2012, till 2019, 1105 aged >18 years verified diagnosis PAH CTEPH, who were subsequently observed at 15 PH expert centers Federation 52 provinces, are included registry on...
Arterial hypertension is both the cause and result of progression chronic kidney disease, which affects about 10-15% population worldwide prevalence steadily increasing. As glomerular filtration rate decreases, blood pressure level rises respectively. (AH) disease (CKD) are independent well-known risk factors for development cardiovascular diseases, their combination significantly increases incidence mortality from disease. Blood control most important factor in slowing CKD reducing risk....
Aim. The aim of current study was to estimate the economic burden chronic thromboembolic pulmonary hypertension (CTEPH) in Russia based on patient registry. Materials and methods. Cost illness data derived from CTEPH registry that developed at Division FSBI “National Medical Research Center Cardiology”. Demographic clinical characteristics were analyzed with descriptive statistic performed state perspective bottom-up approach. Bootstrapping used for calculation average costs per...
Aim: to perform the complex analysis of clinical, functional, hemodynamics profile in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) compared idiopathic arterial (IPAH) group at time diagnosis verification according Russian registry, and evaluate features medical therapy it’s influence on prognosis these patients. Materials methods. In retrospective study 193 IPAH 130 CTEPH older than 18 years were included. All included participants registry...
Aim . To study the features of anticoagulant and specific therapy in newly diagnosed patients with chronic thromboembolic pulmonary hypertension (CTEPH) depending on operability status. Material methods The included 319 CTEPH, hospitalized for first time E.I. Chazov National Medical Research Center Cardiology period from 2012 to 2021. diagnosis was established according current guidelines. Depending status, which assessed by a multidisciplinary team, two following groups were formed:...
Human immunodeficiency virus (HIV) infection is characterized by high morbidity and a significant threat to human health, increasing global mortality. The number of people living with HIV estimated the United Nations Joint Program on Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (UNAIDS) be 39 million (33.1-45.7 million) in 2022. With introduction highly effective antiretroviral therapy (cART) into clinical practice resulting increase life expectancy this cohort patients,...
Aim. To assess demographic and clinical characteristics, to describe of the functional hemodynamic status, profile concomitant pathology, data instrumental examination in chronic thromboembolic pulmonary hypertension (CTEPH) patients; study features specific supportive therapy according Russian national registry. Materials methods. From 2012 till 2020 a multicenter, prospective 15 regional expert centers Federation (www.medibase.pro) included 404 newly diagnosed CTEPH patients over age 18...
Changing the "portrait" of patients with idiopathic pulmonary hypertension (IPH) and chronic thromboembolic (CTPH) over past decade suggests need to develop models phenotypes in this cohort. The purpose study was estimate nature disease course prognosis IPH inoperable CTPH based on formation phenotypic groups depending comorbid status. Materials Methods . Patients (n = 88) 38) aged 38.5 [28.5; 51] 53.5 [41; 58] years respectively were enrolled study. 6-minute step test (6-MST)...
This clinical case illustrates the diagnosis of a rare congenital pathology – an adult patient with pulmonary arterial hypertension and Abernethy malformation type Ib. Clinical observation: Patient S., 45 years old, hypertension, was admitted complaints shortness breath during intense physical exertion. Based on anamnesis morbi, idiopathic has been verified since 2017. Results comprehensive examination: functional status (six-minute walk test), NTpro-BNP level, chest x-ray, echocardiography,...
Objective: development of a questionnaire for the early detection pulmonary arterial hypertension (PAH), and its further introduction broad routine medical practice.Were identified clinical symptoms, allowing differentiate various forms disease (IPAH PAH-CHD), because these PAH most frequent in cardiology practice.Material methods. The includes 6 sections: physical examination, anamnestic information, diseases associated with hypertension; signs according to electrocardiography, chest...
Currently, treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic (CTEPH) is focused on three signaling pathways: the NO pathway, endothelin prostacyclin pathway. Riociguat only representative stimulators soluble guanylate cyclase (sGC) class that approved for PAH inoperable persistent/recurrent CTEPH. The review presents data from clinical trials showing a positive effect riociguat functional hemodynamic profile patients with In recent years there has been much...
Presents data on the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH), which serve as a rationale for approaches to choice treatment. CTEPH usually begins with persistent obstruction large and/or medium arteries by organized thrombi. Impaired lysis thrombi may be associated abnormal fibrinolysis, hematological or autoimmune diseases. The molecular processes underlying lesions small vessels are not fully understand. degree small-vessel disease has significant impact...
Pulmonary arterial hypertension associated with systemic sclerosis (SSc-PAH) and idiopathic pulmonary (IPAH) belong to group I in the clinical classification of PH, but there is evidence for significant differences their survival due current therapy. Objective: objective this report compare pts based on data Russian National Registry. Patients methods: study we included 52 IPAH 50 SSc-PAH. There were no functional class (FC). Diagnosis was RHC. Results. At moment diagnosis average age...
The coronavirus disease of 2019 (COVID-19) is an infectious caused by severe acute respiratory (SARS-CoV-2). This virus has many factors in its pathogenesis that affect the function right ventricle and pulmonary hemodynamics, which can negatively influence clinical course IPAH. According to results our study, fact getting over COVID-19 patients with IPAH leads some changes laboratory instrumental parameters. But no significant effect on risk modification during year was detected. result be...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a precapillary type of with chronic obstruction large and medium branches arteries along secondary alterations in microcirculation, which cause progressive increases vascular resistance arterial pressure ensuing severe right heart dysfunction failure. Pulmonary thromboendarterectomy (PTE) the treatment choice for CTEPH; however, this procedure available not all patients. Although surgery performed conditions centers advanced experience...
The aim of the multicenter prospective open study: to assess demographic and clinical characteristics PAH patients, regions their accommodation, features diagnostic medical strategy, survival. Materials methods. In study we included patients (group 1) aged >18 years observed in 10 expert centers Russian Federation from 01.01.2012 30.04.2014. Patients' data were brought electronic forms on registry site www.pul-hyp.medibase.ru. Results. 198 (160 women/38 men) 44 country 55.0% - IPAH, 35.9%...
Aim: to study the influence of riociguat on functional and hemodynamic status, remodeling right heart, as well safety therapy in both previously untreated patients with idiopathic pulmonary arterial hypertension (IPAH) inoperable chronic thromboembolic PH (CTEPH), those not achieved treatment goals sildenafil switching riociguat. Materials methods. A total 161 pts precapillary were included study; 137 completed three-year observation period. Of 55 IPAH was started after diagnosis...